Canada Pension Plan Investment Board
PTGX icon

Canada Pension Plan Investment Board’s Protagonist Therapeutics PTGX Stock Holding History

Canada Pension Plan Investment Board’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-55,000
Closed -$1.43M – 1321
2021
Q1 		$1.43M Buy
+55,000
New +$1.39M ﹤0.01% 933
2020
Q1 		– Sell
-250,000
Closed -$1.76M – 1440
2019
Q4 		$1.76M Buy
+250,000
New +$2.48M ﹤0.01% 891

Other funds holding PTGX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Canada Pension Plan Investment Board's PTGX Position: Q2 2021 in Review

Canada Pension Plan Investment Board sold out of Protagonist Therapeutics (PTGX) in Q2 2021, closing a stake of 55,000 shares — an estimated $1.43M sold.

Canada Pension Plan Investment Board first reported a position in PTGX in Q4 2019 and held it in 2 quarters. The position peaked at $1.76M in Q4 2019. 138 funds tracked by Wall St. Rank hold PTGX as of Q2 2021.

  • Canada Pension Plan Investment Board reported no remaining Protagonist Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Canada Pension Plan Investment Board sold 55,000 Protagonist Therapeutics shares in Q2 2021, an estimated $1.43M.
  • Canada Pension Plan Investment Board first reported a position in Protagonist Therapeutics in Q4 2019 and held it in 2 quarters.
  • Canada Pension Plan Investment Board's Protagonist Therapeutics position peaked at $1.76M in Q4 2019.
  • 138 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2021.

Based on Canada Pension Plan Investment Board's 13F filing for Q2 2021, filed 16 Aug 2021.